Tycho H. Heimbach, Ph.D.
Affiliations: | 2003 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Pharmacy, Pharmaceutical ChemistryGoogle:
"Tycho Heimbach"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Gordon L. Flynn | grad student | 2003 | University of Michigan | |
| (Oral phosphate prodrugs: Absorption rate limit considerations.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pepin X, Arora S, Borges L, et al. (2024) Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report. Molecular Pharmaceutics |
| Wang M, Heimbach T, Zhu W, et al. (2024) Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space. The Aaps Journal. 26: 69 |
| Wu D, Liu J, Paragas EM, et al. (2024) Assessing and mitigating pH-mediated DDI risks in drug development - formulation approaches and clinical considerations. Drug Metabolism Reviews. 1-20 |
| Mackie C, Arora S, Seo P, et al. (2024) Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Molecular Pharmaceutics. 21: 2065-2080 |
| Wu F, Mousa Y, Jereb R, et al. (2024) Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products. The Aaps Journal. 26: 19 |
| Tsakalozou E, Mohamed MF, Polak S, et al. (2023) Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary. The Aaps Journal. 25: 96 |
| Bauer A, Berben P, Chakravarthi SS, et al. (2023) Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group. Pharmaceutical Research |
| Wu F, Mousa Y, Raines K, et al. (2022) Regulatory Utility of Physiologically Based Pharmacokinetic Modeling to Support Alternative Bioequivalence Approaches and Risk Assessment: A Workshop Summary Report. Cpt: Pharmacometrics & Systems Pharmacology |
| Wu D, Sanghavi M, Kollipara S, et al. (2022) Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs. Pharmaceutical Research |
| Lin W, Chen Y, Unadkat JD, et al. (2022) Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharmaceutical Research |